Purpose: Rhino-orbital-cerebral mucormycosis (ROCM) is a rare opportunistic fungal infection with a fulminant course and an often fatal outcome. It can occur in immune-compromised patients such as those having uncontrolled diabetes, on long-term corticosteroid or immunosuppressive therapy, with COVID-19 infection, renal failure, AIDS, malignancy, or organ transplant. The aim of our study was to study the epidemiology of mucormycosis in COVID-19 patients and identify its risk factors. Methods: Ours was an epidemiological study wherein we gathered the demographic, clinical, histopathological, and radiological data of 458 patients of mucormycosis who presented to us between August 2020 and May 2021. Mucormycosis was defined through clinical and radiological findings or positive culture reports. Results: Out of all, 20.74% of patients did not have any past or concurrent history of COVID-19. The most common symptom of mucormycosis was orbital/facial pain (38.64%) and the most common sign was periorbital/facial edema (50.74%). Mucormycosis involving the nose and sinuses (94.54%) was most common followed by rhino-orbital (45.41%) and brain involvement (10.04%). The most common risk factor for mucormycosis was diabetes (81.92%), followed by corticosteroid use (79.69%) and supplemental oxygen [48.90%]. Most of the patients received similar treatment with IV amphotericin B [88.64%] and local debridement [80.74%]. Conclusion: With the third wave of COVID-19 still lurking, a fatal fungal infection should be kept in mind in COVID-19 active as well as recovered patients, especially those who have co-morbid medical conditions such as uncontrolled diabetes and who are treated with large doses of corticosteroids.

Key words: COVID-19, diabetes, fungal infection, opportunistic, rhino-orbital-cerebral mucormycosis

COVID-19 pandemic, an outbreak of coronavirus disease, was first identified in December 2019. The severity of the disease has been ranging from asymptomatic infection to respiratory failure and death.[1] Secondary fungal or bacterial infections or co-infections are important challenges, which increase the patients’ morbidity and mortality.[1] Mucormycosis is currently a common fungal infection reported as a superinfection in COVID-19 patients.[2]

Zygomycetes comprises mucorales and entomophthorales. The former order causes life-threatening fungal infections such as mucormycosis mainly in immuno-compromised hosts, whereas the latter order causes superficial and mucocutaneous infections in immuno-competent hosts. Among the family of Mucoraceae, Rhizopus oryzae is the most common cause of infection.[3] Phagocytes are the major host defense mechanism against mucormycosis.[4] Systemic corticosteroid treatment affects the ability of these macrophages to prevent the germination of the fungal spores. The inappropriate use of corticosteroids for modulating immune-related lung injury and reducing the mortality rate in COVID-19 patients needing respiratory support and supplementary oxygen may predispose the patients to secondary infections, ultimately increasing the risk of mortality.[5] Uncontrolled diabetes mellitus is also the most common risk factor identified in patients with mucormycosis in COVID-19.[6] A hallmark of mucormycosis infection is the presence of extensive angioinvasion with resultant vessel thrombosis and tissue necrosis.[7] The infection can directly spread into the paranasal sinuses and then invade into orbital and intracranial spaces by direct spread or via the bloodstream.[8] This form is rhino-orbito-cerebral mucormycosis (ROCM) is the most common type of human mucormycosis.[9]

The second wave of COVID-19 disease has seen a surge in the incidence of invasive mucormycosis. We have come across hundreds of cases having varied presentations and outcomes. We conducted a study of ROCM in an attempt to study its epidemiology and risk factors. As per our knowledge, these data are the highest series reported from a single-center to date. With the possibility of further spikes of COVID-19, the study results may guide the prevention of another mucor epidemic.

Methods

Ours is an epidemiological study wherein we report the details of 458 patients of mucormycosis who presented to us between
August 2020 and May 2021 at our tertiary referral center, which is attached to a major COVID-19 hospital. The study was carried out maintaining patient confidentiality and in accordance with ethical standards and the Declarations of Helsinki.

The patients presented either with a concurrent or past history of COVID-19 infection along with clinical features of mucormycosis. The diagnosis of COVID-19 was based on the RT-PCR test of nasopharyngeal swabs. Proven mucormycosis was defined through clinical and radiological findings or positive culture reports. For all patients, we noted their demographic, clinical, histopathological, and radiological data. Based on clinical suspicion, a deep nasal swab was taken by the Otorhinolaryngology (ENT) department and sent for KOH (Potassium Hydroxide) mount and fungal culture. Magnetic resonance imaging (MRI) brain with orbit and paranasal sinus with/without CT scan was performed for assessing the extent of disease. Based on the radiological and nasal swab report, in conjunction with ENT and dental specialists, liposomal or deoxycholate amphotericin B was given intravenously with monitoring of renal parameters. Following clinical and radiological analysis, all patients were categorized into possible, probable, and proven ROCM. Endoscopic sinus debridement was performed and specimens were sent for histopathology and microbiology assessment. Orbital exenteration was advised in patients with suboptimal response to systemic antifungal treatment and who had an intracranial extension and performed after stabilization of general condition.

Results

Our study included 458 patients of ROCM, 285 of which were males and 173 were females. In males as well as females, the maximum number of patients were in the age group of 45–59 years [Table 1]. The geographical distribution of the residence of the patients is shown in Fig. 1. The data regarding the possible risk factors for ROCM has been shared in Tables 2 and 3. Table 4 shows the clinical features of ROCM. The most common symptom of mucormycosis was orbital/facial pain (177 [38.64%] patients) and the most common sign was periorcular/facial edema (237 [50.74%] patients) [Figs. 2-4]. The mean duration of post-COVID-19 development of mucormycosis symptoms was 15.82 ± 11 days. The most common associations in decreasing order were steroid use 365 (90.35%), followed by diabetes 376 (81.92%), oxygen supplement 224 (62.22%), use of injection remdesivir 214 (52.71%), oral zinc supplement 151 (52.61%), regular steam inhalation 64 (28.19%), hypertension 95 (20.74%), and use of ayurvedic medications 43 (16.10%). Table 5 shows the diagnostic tests used for confirmation of diagnosis, Table 6 shows the geographical distribution of mucormycosis patients.

![Table 1: Demographic data](image1)

| Age (years) | Male | Female | Total (%) |
|-------------|------|--------|-----------|
| 0-14        | 0    | 0      | 0         |
| 15-29       | 12   | 0      | 12 (2.62%)|
| 30-44       | 60   | 37     | 97 (21.17%)|
| 45-59       | 124  | 72     | 196 (42.79%)|
| 60-74       | 82   | 51     | 133 (29.03%)|
| ≥75         | 7    | 14     | 20 (4.36%) |
| Total       | 285  | 173    | 458 (100%) |

![Figure 1: Geographical distribution of mucormycosis patients](image2)

![Figure 2: Clinical photograph showing complete lid ptosis with proptosis and conjunctival chemosis](image3)

![Figure 3: Clinical photograph showing corneal melting with a periorbital blackish scar](image4)
Table 3: Risk factors

| Probable risk factor                  | Yes                  | No                  | Data not available |
|---------------------------------------|----------------------|---------------------|--------------------|
| Co-morbidity                          |                      |                     |                    |
| Diabetes                              | 376 (81.92%)         | 82 (17.90%)         |                    |
| Hypertension                          | 95 (20.74%)          | 363 (79.26%)        |                    |
| Supplement oxygen taken               | 224 (62.22%)         | 136 (37.78%)        | 98 (21.39%)        |
| History of steroid                    | 365 (90.35%)         | 39 (9.65%)          | 54 (11.79%)        |
| History of remdesivir                 | 214 (52.71%)         | 192 (47.29%)        | 52 (11.35%)        |
| History of regular steam inhalation   | 64 (28.19%)          | 163 (71.81%)        | 231 (50.44%)       |
| History of ayurvedic medication taken | 43 (16.10%)          | 224 (83.90%)        | 191 (41.70%)       |
| History of oral zinc supplement        | 151 (52.61%)         | 136 (47.39%)        | 171 (37.34%)       |

Table 4: Clinical features

| Presenting symptoms                  | No. of patients (n=458) | Presenting signs                  | No. of patients (n=458) |
|--------------------------------------|-------------------------|-----------------------------------|-------------------------|
| Orbital/facial pain                  | 177 (38.64%)            | Periocular/facial edema           | 237 (51.74%)            |
| Orbital/edema                        | 131 (28.60%)            | Ptosis                            | 53 (11.57%)             |
| Nasal block                          | 41 (8.95%)              | Nasal discharge                   | 47 (10.26%)             |
| Ptosis                               | 38 (8.29%)              | Periocular hypoesthesia           | 15 (3.27%)              |
| Nasal discharge                      | 34 (7.42%)              | Periocular/facial discoloration   | 07 (1.52%)              |
| Loss of vision                       | 07 (1.52%)              | Loss of vision                    | 07 (1.52%)              |
| Proptosis                            | 04 (0.87%)              | Proptosis                         | 04 (0.87%)              |
| Diplopia                             | 02 (0.43%)              | Diplopia                          | 02 (0.43%)              |
| Orbital/facial discoloration         | 02 (0.43%)              | Nasal ulcer/eschar                | 02 (0.43%)              |

Table 5: Microbiological tests for confirmation of diagnosis

| Confirmation of diagnosis (microbiological) | No. of patients* |
|---------------------------------------------|------------------|
| KOH                                         | 375 (89.50%)     |
| Smear                                       | 17 (4.06%)       |
| Culture                                     | 27 (6.44%)       |
| Total                                       | 419              |

*For 39 patients, data were not available

Table 6: Organ involvement

| Organ involvement | No. of patients |
|-------------------|-----------------|
| Nasal cavity      | 44 (9.60%)      |
| PNS involvement   |                 |
| Unilateral        | 187 (48.07%)    |
| Bilateral         | 202 (51.93%)    |
| Orbit             |                 |
| Unilateral        | 173 (83.17%)    |
| Bilateral         | 35 (16.83%)     |
| 208 (45.41%)      |                 |
| 208 (45.41%)      |                 |
| Brain             | 46 (10.04%)     |

shows organ involvement, Table 7 shows ROCM staging, and Table 8 shows definitive treatment of patients.

Discussion

Mucormycosis is an acute and potentially fatal fungal infection caused by fungi related to the Mucoraceae family. These fungi are opportunistic organisms and can be found in fruit, soil, feces and may be cultured from the nasal and oral mucosa of healthy humans. The pathogen as an asexual spore-forming fungus can infect the oral and nasal cavities through inhalation. In the presence of a normal immune system, the spores are removed by phagocytic leukocytes. The pathogen can transform into hyphae form in individuals with predisposing factors such as uncontrolled diabetes (particularly in the presence of ketoacidosis), malignancy (such as lymphoma and leukemia), renal failure, organ transplantation, advanced rheumatologic disorders using immunosuppressive agents (e.g., prolonged use of corticosteroids), AIDS, extensive burns, and chronic sinusitis. In these conditions, leukocytes have less efficacy on the hyphae forms of fungi and the pathogen may proliferate more easily. The organism proliferates and invades the vessel walls of the infected region, resulting in thrombosis, ischemia, and necrosis. It can directly spread into the paranasal sinuses and invade into orbital and intracranial spaces. The symptoms presenting in ROCM are facial pain and paresthesia, headache, periorbital and nasal swelling, inflammation, eyelid drooping, proptosis, external and internal ophthalmoplegia, visual loss, and blackish necrosis of palate and nasal mucosa. The disease usually starts from the nasal and oral mucosa, spreads to the paranasal sinuses, and advances into the orbital space through the lamina papyracea. Vision loss may occur due to the involvement of the optic nerve or vessels supplying the retina. The intracranial space can be involved either directly through the orbital orifices and sinus walls or blood. cavernous sinus thrombosis as another complication results in damage to the cranial nerves III, IV, V1, V2, and VI. Regular examination and imaging (CT and MRI) are crucial to detect the propagation of the mucormycosis. Based on the infected region, the imaging findings may include opacification of involved paranasal sinuses, bone destruction of sinus walls, alterations of intraorbital tissue signal with or without focal mass, cavernous sinus filling defect, intracranial focal mass, and/or alteration of the meningeal signal.
Table 7: ROCM grading[9]

| Stage of ROCM at diagnosis | 1  | 2  | 3  | 4  |
|----------------------------|----|----|----|----|
| No. of patients (n=458)    | 44 (9.61%) | 199 (43.45%) | 169 (36.90%) | 46 (10.04%) |

Table 8: Primary definitive treatment for ROCM

| Primary management | No. of patients |
|--------------------|-----------------|
| Amphotericin B     | 406 (88.64%)    |
| Posaconazole       | 22 (4.80%)      |
| Isavuconazole      | 0               |
| Functional endoscopic sinus surgery (FESS) | 370 (80.78%) |
| Exenteration       | 19 (4.14%)      |

ROCM is a relatively fatal infection and in cases of brain involvement, mortality rises to 50%–85%. Survival depends on timely diagnosis, alleviation of predisposing factors, aggressive debridement of necrotic tissues, and appropriate systemic antifungal therapy. Predisposing factors such as corticosteroid therapy should be discontinued, and blood sugar should be controlled restrictively. Systemic amphotericin B and its liposomal formulation are the first drug of choice for the treatment of mucormycosis and significantly improve the survival rate. Posaconazole is an oral antifungal used as step-down therapy after initial treatment by amphotericin B. Regular daily debridement of necrotic tissues from paranasal sinuses is necessary to prevent the propagation of mucormycosis. Irrigation of the sinuses and the involved regions with diluted amphotericin B has also been recommended. Orbital exenteration may be done in the presence of widespread necrosis.

The Collaborative Occuloplasty Association of India, Indian Journal of Ophthalmology (OPAI-IJO) Study on mucormycosis in COVID-19 (COSMIC), report one published data of 2,826 patients of COVID-19-associated ROCM from all over India. In their report, the mean duration of symptoms of ROCM was between days 10 and 15 from the diagnosis of COVID-19. Fifty-seven percent of the patients needed oxygen support for COVID-19 infection, 87% were treated with corticosteroids, (21% for > 10 days), and diabetes mellitus (DM) was present in 78% of patients. In our study, the mean duration of post-COVID-19 development of mucormycosis symptoms was between days 5 and 25, steroid use was noted in 79.69% and the need for oxygen supplement was seen in 48.90%. Study of COVID-19-associated mucormycosis from western India by Shweta Walia et al. reported 540 proven cases of mucormycosis. In their study also, the most common presentation was periorcular and facial swelling. Ninety-seven percent of the patients had associated diabetes, 89.44% of patients had a history of COVID-19 along with a concurrent history of steroid use. An association with the use of higher antibiotics (82.59%), oxygen therapy (52.40%), and injection remdesivir (28.89%) was also noted. Another study reported by Ajay et al. included 67 cases of COVID-19-associated mucormycosis. In their study also, uncontrolled diabetes (90%) with ketoacidosis (40%) and the use of systemic steroids (84%) were strong predisposing factors. A case series of invasive mucormycosis in patients with COVID-19 infection published by Mishra et al. reported 10 cases of mucormycosis in COVID-19 or post-COVID-19 patients. In their study, nine patients underwent functional endoscopic sinus surgery (FESS) with local debridement and six patients were advised exenteration; however, unfortunately, two patients succumbed to COVID-19 and four did not give consent for the same. Another case report published by Veisi et al. concluded that
patients undergoing corticosteroid therapy for COVID-19 have a higher risk of rhino-orbital and/or rhino-orbito-cerebral mucor, particularly when another risk factor such as diabetes is present. In our series also, 53 patients had prior or COVID-19 precipitated diabetes. A study published by Song et al.[18] investigated 99 patients of fungal infections post-COVID-19 in China and found out that about 5% of these were due to 



Aspergillus and 7% due to Mucor species. They concluded that the impairment of T-cell immunity along with the presence of an underlying immune-compromised state is one of the most important pathogenesis.[6] In a case report published by Mehta et al.[19] reported a case of post-COVID-19 ROCM in which the patient received steroids following the protocols, after which he developed mucormycosis. According to their hypothesis, it could be due to the alterations in the immunity, especially T cells and innate immunity, and the use of steroids could be the cause of invasive fungal infection post-COVID-19.[6] Similar observations have been reported by Werthman–Ehrenreich et al. and Chowdhary et al.[18,19]

Our center being a tertiary referral hospital, the patients presented to us may be exhibiting varying clinical manifestations and could be at varying stages of the disease. Also, they may not necessarily have been treatment-naive patients. In spite of these limitations, these data reflect the incidence and severity of this disease and the common risk factors for the same.

**Conclusion**

From our study, it is apparent that patients with COVID-19 infection are susceptible to mucormycosis because of impairment of barrier defense, dysfunction of phagocytes and lymphocytes, and the use of immunosuppressive medications such as steroids. COVID-19 patients undergoing corticosteroid therapy have a higher risk of rhino-orbital and/or rhino-orbito-cerebral mucormycosis, particularly when another risk factor such as diabetes is present. Other risk factor associations noted were oxygen supplement, use of injection remdesivir, oral zinc supplement, regular steam inhalation, hypertension, and the use of ayurvedic medications. In such susceptible patients, vigilant monitoring for the onset of symptoms is crucial. Early diagnosis and treatment of secondary fungal infections with nasal debride, antifungals, and exenteration can substantially reduce morbidity and mortality.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020;395:1054–62.

2. Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal co-infection among hospitalized patients with COVID-19: A retrospective cohort study in a UK secondary-care setting [published online ahead of print, 2020 Jun 27]. Clin Microbiol Infect 2020;26:1395–9.

3. Ribes JC, Vanover-Sans CL. Zygomycetes in human disease. Clin Microbiol Rev 2000;13:236–301.

4. Waldorf AR. Pulmonary defense mechanisms against opportunistic fungal pathogens. Immunol Ser 1989;47:243–71.

5. Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense mechanisms against Rhizopus. J Clin Invest 1984;74:150–60.

6. Goel S, Palaskar S, Shetty VP, Shetty VP, Bhushan A. Rhinomaxillary mucormycosis with cerebral extension. J Oral Maxillofac Pathol 2009;13:14–7.

7. Afroze SN, Korlepara R, Rao GV, Madala J. Mucormycosis in a diabetic patient: A case report with an insight into its pathophysiology. Contemp Clin Dent 2017;8:662–6.

8. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 2020;324:782–93.

9. Honavar S. Code mucor: Guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19. Indian J Ophthalmol 2021;69:1361–5.

10. Mohindra S, Mohindra S, Gupta R, Bakshi J, Gupta SK. Rhinocerebral mucormycosis: The disease spectrum in 27 patients. Mycoses 2007;50:290–6.

11. Viterbo S, Fasolis M, Garzino-Demo P, Griffa A, Boffano P, Iaquinta C, et al. Management and outcomes of three cases of rhinocerebral mucormycosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112:e69–74.

12. Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report. Eur J Ophthalmol 2021;11206721211009450. doi: 10.1177/11206721211009450.

13. Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: A clinical and diagnostic perspective from China. Mycopathologia 2020;185:599–606.

14. Sen M, Honavar S, Bansal R, Sengupta S, Rao R, Kim U, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbito-cerebral mucormycosis in 2826 patients in India-Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COMS), Report 1. Indian J Ophthalmol 2021;69:1670–92.

15. Walia S, Bhaisare V, Rawat P, Kori N, Sharma M, Gupta N, et al. COVID-19-associated mucormycosis: Preliminary report from a tertiary eye care centre. Indian J Ophthalmol 2021;69:3685–9.

16. Vare A, Yellambkar S, Farheen A, Nandedkar V, Bhombe S, Saha R. Incidence, cumulative mortality and factor affecting the outcome of COVID-19 associated mucormycosis from western India. Indian J Ophthalmol 2021;69:3678–83.

17. Mishra N, Mutya V, Thomas A, Rai G, Reddy B, Mohanan AA, et al. A case series of invasive mucormycosis in patients with COVID-19 infection. Int J Otorhinolaryngol Head Neck Surg 2021;7:867–70.

18. Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus 2020;12:e10726.

19. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med 2021;264:64–8.

20. Chowdhary A, Tarai B, Singh A, Sharma A. Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients, India, April-July 2020. Emerg Infect Dis 2020;26:2694–6.